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Chronic inflammation is well known as a significant driver 
of carcinogenesis in settings of human disease, including 
liver disease and hepatocellular carcinoma (HCC). Hepatitis 
B virus (HBV) is one of the major causes of HCC due to the 
oncogenic nature of the virus and the robust inflammatory 
response in the infected host. Fc receptors (FcR) are 
specialized receptors found on innate immune cells that 
recognize and bind to antigen-presenting antibodies, 
linking the innate and adaptive immune system to respond 
to circulating foreign bodies, such as viral DNA (1). 
Increased B-cell activation and antibody production in 
response to HBV infected liver will lead to increased 
FcR signalling on circulating innate immune cells and 
resident-macrophages (Kupffer cells), further enhancing 
the inflammatory response. Progression to chronic liver 
inflammation is associated with hyperactivity of B cell 
immunity, increasing the risk of cancer development due to 
constant infiltration of immune cells and accumulation of 
damaged hepatocytes. FcR activation has been previously 
implicated in carcinogenesis by creating a ‘pro-tumour 
microenvironment’ within inflammation-mediated damaged 
tissue through promotion of angiogenesis, epithelial 
mesenchymal transition (EMT), and increased cell 
surviva l  (2) .  Of  recent  interest  i s  the polymeric 
immunoglobulin receptor (pIgR), a member of the Fc 
receptor family, that is widely expressed on epithelial cells 
and is responsible for transcytosis of IgA/IgM at mucosal 
surfaces. Few studies have investigated the role of pIgR 
in cancer, although most have implicated pIgR to be 
downregulated in cancers of various epithelial origin (3). In 
this sense, the dysregulation of pIgR in mucosal membranes 
could limit the first line of defence for immunity against 
carcinogenic cells, and possibly contribute to malignant 
transformation. 
In contrast, a previous study identified pIgR to be 
upregulated in colorectal cancers with liver metastasis and 
in HCC patients (4). Ai and colleagues showed that mice 
injected with Madin-Darby canine kidney (MDCK) cells or 
SMMC-7721 cells overexpressing pIgR had increased lung 
metastasis (4). The authors identified pIgR to activate Smad 
signalling and promote EMT in MDCK and SMCC-7721 
cells, as demonstrated by increased migration and invasion 
activity (4). While these results elucidated how increased 
pIgR expression contributed to metastasis of epithelial 
tumours, it remained unknown how overexpression of 
pIgR may contribute to development of primary liver 
tumours. More recently this group was the first to show 
upregulated pIgR expression as a promoter of mesenchymal 
tumour formation (5). This study demonstrated both 
MDCK cells and SMMC-7721 cells overexpressing pIgR 
to have increased colony formation in vitro, including 
as anchorage-independent colonies, and was consistent 
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with previous results (4). Furthermore, the injection of 
mice subcutaneously with these cancer cells resulted in 
significantly increased tumour growth, with a high mortality 
burden compared to control, and demonstrated the striking 
malignancy of this tumour subtype. 
More notably Yue and colleagues are the first to identify 
a novel role for pIgR as part of a signalling cascade involved 
in HCC oncogenic transformation. Through a series of 
gene ablation experiments in vitro, the authors established 
the involvement of a number of down-stream effector 
kinases modulated by increased pIgR activation. In pIgR 
expressing MDCK and SMMC-7721 cells, pIgR formed a 
complex with an adapter protein, DAP12, and Src kinase 
member, Yes, to act as the primary signalling modulator. 
This complex recruited another tyrosine kinase, Syk, to 
activate GTPases Rac1 and Cdc42 which then activated 
MEK/ERK. Furthermore, pIgR was responsible for the 
activation of these downstream kinases, as demonstrated by 
Yes, Syk, and MEK/ERK phosphorylation, and increased 
expression of GTP-bound Rac1/Cdc42 (5). 
The role of ERK in oncogenic transformation is myriad 
and is often stimulated by upstream regulators such as Ras/
Raf, which are mutated in 20% of all human cancers (6). 
c-Myc is a well-known downstream target of ERK, and it 
induces the expression of cyclin D and cyclin-dependent 
kinase (CDK4; G1 phase), cyclin A (S phase), CDK1 
required for mitosis, and CDK kinase inhibitors (CKI) such 
as p27Kip1 (7). ERK also activates ribosomal kinases (RSK) 
like p90RSK that can in turn activate CREB, and the proto-
oncogenes c-Fos, Ets and c-Jun, to promote cell cycle 
promotion, stem cell renewal and differentiation (7-12). In 
addition, ERK can limit cell apoptosis by inactivating Bad/
Bim, inhibitors of anti-apoptotic proteins Bcl-2 and Mcl-
1, allowing Bcl-2/Mcl-1 to inhibit Bak/Bax and prevent 
mitochondrial outer membrane permeability (MOMP), 
release of cytochrome c and thus apoptosis (13). ERK 
also phosphorylates and inactivates caspase 9 to promote 
cell survival, and via CREB/Ets induce Bcl-2 and Bcl-
XL transcription, to limit apoptosis (7). Therefore, pIgR 
stimulated activation of ERK may stimulate a large sequence 
of signalling events to promote tumour cell transformation, 
proliferation and survival (Figure 1). 
Additionally,  Yue and colleagues demonstrated 
significant activation of Rho GTPase members Rac1 and 
Cdc42 (5), which activate p21-activate kinase (PAKs) to 
promote cytoskeleton reorganization for cell motility 
and invasion (14). Thus, increased activity of pIgR/Rac1/
Cdc42 signalling may contribute to tumour cell invasion 
and metastasis, as demonstrated by the high malignancy of 
this tumour subtype in murine models (5). Previous work 
by these authors demonstrated pIgR to activate Smad2/3, 
increasing expression of Snail, Slug, and ZEB1 to repress 
E-cadherin expression and promote EMT (4). Therefore, 
overexpression of pIgR appears to not only contribute to 
continued cell cycle progression leading to cell growth, 
but also stimulates EMT and cell invasion, leading to a 
malignant and potentially metastatic tumour (Figure 1). 
This is consistent with other work that has observed pIgR 
expression to be correlated with colon cancer and liver 
metastasis (15). 
This study also explored pIgR in a clinical setting of 
HCC. Yue and colleagues correlated pIgR positive tumours 
to be significantly correlated to tumours with active Yes/
ERK. Additionally, pIgR/Yes positive tumours were 
associated with worse overall survival and disease-free 
survival in HCC patients, but only significantly in those 
who were further grouped as hepatitis B surface antigen 
(HBsAg) positive, or those with early-stage HCC (5). The 
presence of HBV infection may stimulate the expression 
of pIgR in an attempt to apprehend the circulating virus. 
Thus, the infected cells not only have increased expression 
of pIgR leading to aggressive tumour cell behaviour, but 
are also likely to simulate a large immune response and 
promote liver damage, further increasing the risk of HCC 
development. Other studies have identified increased 
expression of pIgR to be beneficial in preventing aggressive 
tumour formation, due to the contributions towards 
the immune response which may otherwise contribute 
to tumour growth (3). At this stage, it is unclear how 
the relative expression of pIgR contributes as a marker 
of prognosis, as it appears to be tissue dependent. The 
authors investigated the therapeutic potential of targeting 
the pIgR/Yes signalling cascade in an attempt to reduce 
tumour growth with dasatinib and AZD6244, inhibitors of 
Src kinases and MEK, respectively. Mice bearing MDCK 
xenograft tumours exhibited significantly decreased tumour 
volume and prolonged survival in both treatment groups, as 
expected since previous results showed significant increased 
activity of these kinases in this cell line. Mice bearing 
patient-derived pIgR+/Yes+ xenograft tumours showed 
greater reduction in tumour volume compared to the mice 
bearing pIgR-/Yes- patient tumours, although the response 
was considered non-significant (5). It is likely, that pIgR-/
Yes- patient tumours did not respond well to treatment 
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because of the activity of other oncogenic pathways. 
However, the increased sensitivity in the pIgR+/Yes+ 
tumours shows promise for specific patient-targeted therapy. 
Although applications as a primary treatment for HCC 
are unlikely, inhibiting this signalling cascade may provide 
value as a temporary therapeutic option for controlling 
tumour size to allow for resection or transplantation. Future 
investigations should explore the use of these inhibitors in 
clinical trials, and further characterization of this signalling 
cascade is required to confirm the role for pIgR in HCC 
development.
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Figure 1 pIgR signalling in hepatic cancer cell transformation. pIgR forms a complex with DAP12 and the tyrosine-protein kinase Yes 
to activate downstream signalling of MEK/ERK mediated by Syk kinase and Rac1/Cdc42 GTPases. Activated ERK may further activate 
transcription factors involved in promoting expression of cyclins and CDKs required for cell cycle progression. ERK also phosphorylates and 
inactivates pro-apoptotic proteins Bad/Bim and caspase 9 to promote cell survival. pIgR/Yes signalling may also contribute to cell invasion 
and metastasis by stimulation of EMT through Smad signalling and by Rac1/Cdc42-mediated activation of PAK enzymes to increase cell 
motility. CDK, cyclin-dependent kinase; CKI, cyclin kinase inhibitor; EMT, epithelial mesenchymal transition; MOMP, mitochondrial outer 
membrane permeability.
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